INTERNATIONAL COMPARISON OF HTA DECISIONS FOR ORPHAN AND NON-ORPHAN ONCOLOGY DRUGS

被引：0
|
作者：
Achour, L. [1 ]
Hanna, E. [2 ]
Borissov, B. N. [3 ]
Ma, F. [4 ]
Toumi, M. [5 ]
机构：
[1] Paris Dauphine Univ, Paris, France
[2] Creat Ceut, Paris, France
[3] Prescriptia Ltd, Sofia, Bulgaria
[4] Creat Ceut, Beijing, Peoples R China
[5] Aix Marseille Univ, Marseille, France
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.07.174
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN105
引用
收藏
页码：S23 / S23
页数：1
相关论文
共 50 条
  • [1] THE GOOD THE BAD AND THE NON -QUANTIFIABLE - A COMPARISON OF REBATES ON ORPHAN DRUGS VERSUS NON-ORPHAN DRUGS IN GERMANY
    Wijnands, T.
    Schuchardt, M.
    Nijhuis, T.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A582 - A582
  • [2] A REVIEW AND EVALUATION OF SUCCESSFULLY REIMBURSED ORPHAN AND NON-ORPHAN DRUGS IN IRELAND
    Lyttle, S. J.
    Roberts, G.
    Greenwood, M.
    Mumford, A.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S275 - S275
  • [3] HTA OUTCOMES FOR ORPHAN DRUGS IN ONCOLOGY: COMPARISON OF FRANCE, GERMANY AND ENGLAND
    Jaroslawski, S.
    Toumi, M.
    Korchagina, D.
    Auquier, P.
    Dussart, C.
    [J]. VALUE IN HEALTH, 2018, 21 : S111 - S111
  • [4] EU marketing authorization review of orphan and non-orphan drugs does not differ
    Putzeist, M.
    Mantel-Teeuwisse, A. K.
    Llinares, J.
    Gispen-De Wied, C. C.
    Hoes, A. W.
    Leufkens, H. G. M.
    [J]. DRUG DISCOVERY TODAY, 2013, 18 (19-20) : 1001 - 1006
  • [5] Estimating the clinical cost of drug development for orphan versus non-orphan drugs
    Kavisha Jayasundara
    Aidan Hollis
    Murray Krahn
    Muhammad Mamdani
    Jeffrey S. Hoch
    Paul Grootendorst
    [J]. Orphanet Journal of Rare Diseases, 14
  • [6] Estimating the clinical cost of drug development for orphan versus non-orphan drugs
    Jayasundara, Kavisha
    Hollis, Aidan
    Krahn, Murray
    Mamdani, Muhammad
    Hoch, Jeffrey S.
    Grootendorst, Paul
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2019, 14 (1)
  • [7] ORPHAN DRUGS ASSESSMENT IN GERMANY: A COMPARISON WITH OTHER INTERNATIONAL HTA AGENCIES
    Mycka, J.
    Dellamano, R.
    Lobb, W.
    Dellamano, L.
    Dalal, N.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A550 - A551
  • [8] DO HEALTH PLANS COVER ORPHAN AND NON-ORPHAN DRUGS DIFFERENTLY? AN EMPIRICAL ANALYSIS
    Margaretos, N.
    Panzer, A.
    Neumann, P. J.
    Chambers, J.
    [J]. VALUE IN HEALTH, 2019, 22 : S388 - S389
  • [9] Meiosis Research in Orphan and Non-orphan Tropical Crops
    Bolanos-Villegas, Pablo
    Arguello-Miranda, Orlando
    [J]. FRONTIERS IN PLANT SCIENCE, 2019, 10 : 1 - 7
  • [10] HTA ASESSMENT COMPARISON OF ORPHAN DRUGS IN FRANCE AND GERMANY
    Remuzat, C.
    Mzoughi, O.
    Rodrigues, J.
    Korchagina, D.
    Toumi, M.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A236 - A237
12345